New antibiotics need new partnerships
This article was originally published in Scrip
Infections are fast becoming the new neglected diseases. As antibiotics lose their effectiveness against serious bacterial illnesses because of the rise in resistant pathogens, the likelihood is growing that common treatable conditions such as pneumonia and tuberculosis will again become fatal diseases – and not just in developing countries.
You may also be interested in...
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.
The UK’s rapid authorization of the Pfizer/BioNTech COVID-19 vaccine has sparked a public debate over regulatory processes at some of the world’s key regulatory bodies.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.